Cipla Stock Forecast for 2023 - 2025 - 2030
Updated on 03/27/2024
Cipla Stock Forecast and Price Target
The average price target for Cipla's stock of Rp1475.00 recently provided by thirty two leading analysts would represent a -1.93% downside from its last closing price if reached. This potential increase is based on a high estimate of Rp1750.00 and a low estimate of Rp1029.00. If you're thinking of investing in CIPLA stock, it's critical to check out its competitors as well.
-1.93% Downside
Cipla Fair Value Forecast for 2023 - 2025 - 2030
In the last three years, Cipla's Price has grown by 89.35%, rising from Rp538.78 to Rp1020.19. For the next year, analysts predict that Fair Value will reach Rp1368.60 – an increase of 34.15%. Over the next seven years, experts believe that Cipla's Fair Value will grow at a rate of 75.06%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$734.37 | Buy/Sell | $636.99 | 10.71% |
MRK Stock Forecast | Merck | Outperform |
2
|
$122.77 | Buy/Sell | $130.51 | 9.96% |
ABT Stock Forecast | Abbott Laboratories | Outperform |
9
|
$120.19 | Buy/Sell | $118.92 | 4.83% |
NOVN Stock Forecast | Novartis | Outperform |
10
|
CHF88.80 | Buy/Sell | CHF105.00 | 23.95% |
PFE Stock Forecast | Pfizer | Outperform |
2
|
$28.37 | Buy/Sell | $32.87 | 10.82% |
Cipla Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Cipla's Revenue has grown by 32.08%, rising from Rp170.81B to Rp225.59B. For the next year, analysts predict that Revenue will reach Rp257.06B – an increase of 13.95%. Over the next seven years, experts believe that Cipla's Revenue will grow at a rate of 33.57%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
SAN Stock Forecast | Sanofi | Outperform |
16
|
88.32€ | Buy/Sell | 102.80€ | 21.15% |
ZTS Stock Forecast | Zoetis | Outperform |
18
|
$183.49 | Buy/Sell | $220.47 | 20.72% |
SUNPHARMA Stock Forecast | Sun Pharmaceutical Industries | Outperform |
8
|
Rp1.59k | Buy/Sell | Rp1.52k | -1.42% |
Cipla Dividend per Share Forecast for 2023 - 2025 - 2030
In the last three years, Cipla's Dividend per Share has grown, moving from Rp3.00 to Rp8.50 – an increase of 183.33%. For the following year, the 28 analysts predict that Cipla's Dividend per Share will drop by 9.06%, reaching Rp7.73. Looking ahead to seven years, experts forecast that Dividend per Share will grow by 5.49%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
BAYN Stock Forecast | Bayer | Hold |
5
|
26.82€ | Buy/Sell | 45.15€ | 26.77% |
TEVA Stock Forecast | Teva Pharmaceutical Industries | Outperform |
12
|
$13.35 | Buy/Sell | $11.59 | 19.85% |
VTRS Stock Forecast | Viatris Inc | Hold |
8
|
$11.97 | Buy/Sell | $11.73 | 0.25% |
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
500124 Stock Forecast | Dr. Reddy's Laboratories | Hold |
18
|
Rp6.38k | Buy/Sell | Rp5.67k | -6.20% |
DIVISLAB Stock Forecast | Divi's Laboratories | Underperform |
18
|
Rp3.60k | Buy/Sell | Rp3.30k | -7.55% |
DABUR Stock Forecast | Dabur India | Outperform |
18
|
Rp533.40 | Buy/Sell | Rp607.25 | 13.42% |
Cipla EBITDA Forecast for 2023 - 2025 - 2030
Cipla's EBITDA has seen growth In the last three years, going from Rp30.79B to Rp49.19B – a gain of 59.77% In the next year, analysts believe that EBITDA will reach Rp61.10B – an increase of 24.21%. For the next seven years, the forecast is forEBITDA to grow by 44.65%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
500420 Stock Forecast | Torrent Pharmaceuticals | Outperform |
18
|
Rp2.70k | Buy/Sell | Rp2.13k | 3.82% |
IPN Stock Forecast | Ipsen | Outperform |
17
|
106.40€ | Buy/Sell | 127.95€ | 9.96% |
500257 Stock Forecast | Lupin | Hold |
12
|
Rp1.67k | Buy/Sell | Rp1.11k | -8.05% |
Cipla EBIT Forecast for 2023 - 2025 - 2030
In the last three years, EBIT for Cipla has grown by 89.05%, going from Rp21.20B to Rp40.08B. In the coming year, analysts are expecting an increase in EBIT, predicting it will reach Rp50.20B – an increase of 25.25%. Over the next seven years, experts anticipate that EBIT growth for Cipla will be 46.73%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
503806 Stock Forecast | SRF | Outperform |
17
|
Rp2.46k | Buy/Sell | Rp2.48k | 4.77% |
ELAN Stock Forecast | Elanco Animal Health | Outperform |
13
|
$16.02 | Buy/Sell | $14.90 | 12.36% |
500488 Stock Forecast | Abbott India | Outperform |
18
|
Rp27.23k | Buy/Sell | Rp24.75k | 5.19% |
Cipla EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last three years, Cipla's EPS has grown by 89.35%, rising from Rp19.16 to Rp36.28. For the next year, analysts predict that EPS will reach Rp48.67 – an increase of 34.15%. Over the next seven years, experts believe that Cipla's EPS will grow at a rate of 75.06%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
AUROPHARMA Stock Forecast | Aurobindo Pharma | Outperform |
18
|
Rp1.06k | Buy/Sell | Rp1.09k | 10.08% |
500660 Stock Forecast | GlaxoSmithKline Pharmaceutical... | Hold |
18
|
Rp2.01k | Buy/Sell | Rp1.78k | 5.21% |
BIOCON Stock Forecast | Biocon | Hold |
14
|
Rp279.20 | Buy/Sell | Rp270.86 | 2.08% |